AI Verdict
VRTX has stronger fundamentals based on our AI analysis.
REGN vs VRTX Fundamental Comparison
| Metric | REGN | VRTX |
|---|---|---|
| Revenue | $14.3B | $12.0B |
| Net Income | $4.5B | $4.0B |
| Net Margin | 31.4% | 32.9% |
| ROE | 14.4% | 21.2% |
| ROA | 11.1% | 15.4% |
| Current Ratio | 4.13x | 2.90x |
| Debt/Equity | 0.06x | 0.01x |
| EPS | $41.48 | $15.32 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
REGN vs VRTX: Frequently Asked Questions
Is REGN or VRTX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), VRTX has stronger fundamentals. REGN is rated BUY (80% confidence) while VRTX is rated BUY (86% confidence). This is not investment advice.
How does REGN compare to VRTX fundamentally?
REGENERON PHARMACEUTICALS, INC. has ROE of 14.4% vs VERTEX PHARMACEUTICALS INC / MA's 21.2%. Net margins are 31.4% vs 32.9% respectively.
Which stock pays higher dividends, REGN or VRTX?
REGN has a dividend yield of N/A or no dividend while VRTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in REGN or VRTX for long term?
For long-term investing, consider that REGN has BUY rating with 80% confidence, while VRTX has BUY rating with 86% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about REGN vs VRTX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For REGN vs VRTX, the AI consensus favors VRTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.